GLP-1s and Adolescents: What the Labels Allow

This site has covered the older end of the age range, at GLP-1s After 65: What Changes. This page covers the other end, and the labels turn out to have a shape. Read the pediatric sections of every GLP-1 label in the class and two rules fall out cleanly, so cleanly that they organize everything else on this page. The diabetes products have one age floor and the weight products another. And the brand on the box decides more than the molecule inside it.

Two age floors, and a table of what is actually allowed

On the diabetes side, the floor is 10. Every GLP-1 product with a pediatric indication for type 2 diabetes, Mounjaro, Trulicity and Victoza, is established in patients aged 10 years and older. On the weight side, the floor is 12. Both products with a pediatric weight indication, Wegovy and Saxenda, start at 12 years, and Saxenda adds a condition of its own: a body weight above 60 kg. That is the whole pattern, and the table below is the complete list of pediatric statements in the class, no more and no less.

The adult versions of all of these uses, and the other indications the class has accumulated, are consolidated at What GLP-1s Are Actually Approved to Treat. The pediatric picture is narrower, and the narrowing is not uniform: it follows the trials, which is the subject of the next two sections.

The brand matters more than the molecule

Here is the detail that surprises most people. Tirzepatide is established in children only as Mounjaro, for type 2 diabetes. It is not established as Zepbound, for weight, whose label states plainly that safety and effectiveness have not been established in pediatric patients. Semaglutide is the mirror image: established in children only as Wegovy, for weight reduction, while Ozempic, the same molecule sold for diabetes, states that safety and efficacy have not been established in pediatric patients.

Same molecules, opposite answers. Nothing about the chemistry decides this. Each brand is a separate approval built on its own trials, and a company that runs a pediatric program for one brand has no reason the regulator would automatically extend it to another. The adult versions of this same argument, that the brand and its label are the unit that matters, are made at Mounjaro vs Zepbound: Same Molecule, Different Labels and Ozempic vs Wegovy: Same Molecule, Different Rules. For families it lands as a practical point: the question is never whether semaglutide or tirzepatide is approved for adolescents. The question is whether a specific brand is, for a specific purpose.

Small trials, real indications

The trials behind these indications deserve their own accounting, because their sizes say something honest about the evidence. Wegovy's pediatric indication rests on a 68-week, double-blind, placebo-controlled trial in 201 patients. Saxenda's rests on a 56-week double-blind trial. Mounjaro's rests on a 30-week randomized, double-blind, placebo-controlled trial with a 22-week open-label extension in 99 pediatric patients. Trulicity's rests on a 26-week trial in 154 pediatric patients, and Victoza's on a 26-week placebo-controlled trial with a 26-week open-label extension in 134 patients aged 10 to 17.

Those are small numbers beside the adult programs, whose flagship trials enrolled many thousands. The consequence is worth stating plainly: the evidence base for adolescents is thinner than for adults even where an indication exists. Fewer patients means less known about rare effects and about longer horizons. That is not an argument that the indications are unsound; they were granted on the evidence regulators required. It is a description of how much is known, and a family weighing any of this deserves the description rather than a slogan.

Two ceilings that sit lower than the adult ones

Beyond age floors, two products carry pediatric dose ceilings that differ from their adult labels, and this is a real prescribing difference rather than a technicality. Mounjaro's maximum dosage in pediatric patients is 10 mg once weekly, against 15 mg in adults. Trulicity's pediatric maximum is 1.5 mg once weekly, against 4.5 mg in adults. Both belong in the prescribing conversation, not in this page's table, because a ceiling is a limit a prescriber works within, not a target anyone should aim for. Nothing here advises any dose, any change, or any comparison between them.

GLP 1 Tracker AppShot day, dose, site and a note on how the week went, all dated and private on the phone. Whatever a pediatrician asks at the next visit, the record is what makes the answer specific. Get the app

Who decides, and what a parent actually does

Everything clinical on this page stays with the prescriber. Whether a GLP-1 belongs in an adolescent's care at all, which brand, at what point, and for how long, are judgments made with the patient's full history, and this article reports labels without arguing either direction. What a parent or guardian does is practical: get the prescriptions filled, keep the pen in the fridge, notice the weeks, and hold the record.

If the person doing the tracking is not the person taking the medicine, consent is the word that matters, and it matters more with a teenager, not less. Tracking on someone else's behalf works when the person being tracked agrees to it, and a 14-year-old who has agreed to their parent logging their shot days is in a very different position from one who has not found it out. Tracking a Family Member’s GLP-1 Journey, With Consent covers the mechanics: what to record, where it lives, and how consent is asked for rather than assumed. The same app supports a note attached to each dose entry, which belongs to whoever made it.

One boundary keeps the whole subject in proportion. Adolescence is the one population where several brands are established and several are not, sometimes the same molecule in both columns. That is unusual, and it means the label is doing real work here. The pages linked above read each relevant section; the label itself, and the prescriber who reads it alongside everything else a label cannot see, are where the answers are.